Study suggests experimental drug dismantles 2 key proteins that help tumors survive, adapt and resist treatment
Scientists from Roswell Park Comprehensive Cancer Center report that the investigational anticancer agent FL118 functions as a dual molecular glue degrader that directly targets and degrades the proteins DDX5 and UbE2T, two emerging therapeutic targets linked to cancer survival mechanisms.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
